Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sanofi 2 ADR Representing Ord Shs SNY

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more

Recent & Breaking News (NDAQ:SNY)

FDA approves Toujeo® Max SoloStar®

PR Newswire March 27, 2018

Sanofi successfully prices EUR 8 billion of bond issues

GlobeNewswire March 15, 2018

Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

Canada NewsWire March 10, 2018

Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need

PR Newswire March 10, 2018

Sanofi: Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate

GlobeNewswire March 10, 2018

Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate

PR Newswire March 10, 2018

Sanofi Completes Acquisition of Bioverativ Inc.

GlobeNewswire March 8, 2018

Evotec and Sanofi in exclusive talks to create an Evotec-led Infectious Disease open innovation R&D platform

GlobeNewswire March 8, 2018

Sanofi: Filing of the 2017 U.S. Form 20-F and French « Document de Référence » containing the Annual Financial Report

GlobeNewswire March 7, 2018

Sanofi's Board of Directors Proposes Appointment of Emmanuel Babeau as New Independent Director

GlobeNewswire March 6, 2018

7 Biotech Stocks With Clinical Trial Outcomes In March

Benzinga.com  March 5, 2018

Sanofi : FDA to review Dupixent® (dupilumab) as potential treatment for moderate-to-severe asthma

GlobeNewswire March 2, 2018

Novavax Shares Rise 30% On Positive Data, But Risks Remain

Benzinga.com  March 1, 2018

Benzinga Pro's 4 Stocks To Watch Today

Benzinga.com  March 1, 2018

Sanofi Announces Receipt of Antitrust Clearances in Connection with the Acquisition of Ablynx

GlobeNewswire March 1, 2018

25 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  February 12, 2018

First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent™, now available in Canada

Canada NewsWire February 8, 2018

Sanofi Commences Tender Offer for Acquisition of Bioverativ Inc.

GlobeNewswire February 8, 2018

Sanofi Delivers 2017 Business EPS in line with Guidance

PR Newswire February 7, 2018

Sanofi to Host Earnings Call

Accesswire February 7, 2018